Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.63 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1411057 | 0.80 | HDAC2 (0.64) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL1410848 | 0.80 | HDAC2 (0.64) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL1410846 | 0.80 | HDAC2 (0.64) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL1411061 | 0.80 | HDAC2 (0.64) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL19712547 | 0.80 | HDAC2 (0.64) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL8278533 | 0.77 | HDAC1 (1.00) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL13949978 | 0.77 | HDAC1 (0.72) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL12027931 | 0.77 | HDAC2 (0.59) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL13762663 | 0.76 | HDAC8 (0.77) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL15482227 | 0.76 | HDAC8 (0.70) | HDAC1HDAC2HDAC8HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | NOVARTIS AG | 2009-01-08 | — | — | US | disclosed |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | NOVARTIS AG | 2009-01-08 | — | — | US | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1870399-A1 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| EP-1318980-B1 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007021682-A1 | METHOD OF USE OF DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176849-A1 | DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC2 9/4885HDAC8 10/4885 |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | HDAC3, HDAC5, HDAC1 | HDAC1 3/4885HDAC2 7/4885HDAC8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.